TP53 rs1042522 polymorphism and early-onset breast cancer
- PMID: 32419782
- PMCID: PMC7213006
- DOI: 10.4103/jrms.JRMS_506_19
TP53 rs1042522 polymorphism and early-onset breast cancer
Abstract
Background: Breast cancer is the leading cause of cancer deaths among women. Early-onset breast cancer is well recognized as it clinically differs from old-age diagnosed breast neoplasms. TP53 rs1042522 polymorphism relates to the risk of breast neoplasms, but this relationship in Turkish early-onset breast cancer patients has not been investigated yet. We aimed to search the relationship between TP53 rs1042522 polymorphism and young Turkish breast cancer patients.
Materials and methods: Ninety-six female breast cancer patients who were ≤ 40 years of age and 96 healthy controls were enrolled in our study. Participants were genotyped by the hybridization probe system.
Results: We identified that the genotype frequencies of rs1042522 were significantly different between controls and cases (P = 0.027). Participants carrying CG genotype had also reduced breast cancer risk (odds ratio = 0.4196, 95% confidence interval: 0.1941-0.9067, P = 0.027). Our results revealed that there is an association between GG and CG + CC genotype groups with progesterone receptor (PgR) status (P = 0.0219).
Conclusion: Our findings indicate that the CG genotype is a protective factor against breast neoplasms. No other clinicopathologic parameters except for PgR status were found to be related to rs1042522 polymorphism in young Turkish breast cancer patients.
Keywords: Breast neoplasms; TP53; early onset; genotype; rs1042522.
Copyright: © 2020 Journal of Research in Medical Sciences.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta-analysis.Chronic Dis Transl Med. 2017 May 25;3(2):95-104. doi: 10.1016/j.cdtm.2017.04.001. eCollection 2017 Jun 25. Chronic Dis Transl Med. 2017. PMID: 29063062 Free PMC article.
-
Association of TP53 rs1042522 with cervical cancer in the sub-Saharan African population: a meta-analysis.Trop Med Int Health. 2020 Jun;25(6):666-672. doi: 10.1111/tmi.13397. Epub 2020 Apr 16. Trop Med Int Health. 2020. PMID: 32233050
-
The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.Aging (Albany NY). 2017 Mar 8;9(3):852-859. doi: 10.18632/aging.101196. Aging (Albany NY). 2017. PMID: 28275206 Free PMC article.
-
[Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Feb;47(2):124-8. Zhonghua Yu Fang Yi Xue Za Zhi. 2013. PMID: 23719102 Chinese.
-
Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies.Gene. 2020 Apr 15;734:144391. doi: 10.1016/j.gene.2020.144391. Epub 2020 Jan 27. Gene. 2020. PMID: 32001373 Review.
Cited by
-
The Genetic Changes of Hepatoblastoma.Front Oncol. 2021 Jul 21;11:690641. doi: 10.3389/fonc.2021.690641. eCollection 2021. Front Oncol. 2021. PMID: 34367972 Free PMC article. Review.
-
The Investigation of Associations between TP53 rs1042522, BBC3 rs2032809, CCND1 rs9344, EGFR rs2227983 Polymorphisms and Breast Cancer Phenotype and Prognosis.Diagnostics (Basel). 2021 Aug 5;11(8):1419. doi: 10.3390/diagnostics11081419. Diagnostics (Basel). 2021. PMID: 34441352 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed
-
- Azim HA, Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341–51. - PubMed
-
- Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 2001;19:3817–27. - PubMed
-
- Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr, Deshler A, et al. National institutes of health consensus development conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979–89. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous